What question did this study set out to answer?

The goal is to identify 1-year predictors of pulmonary hypertension in patients treated with transcatheter interventions.

April 1, 2026

Clinical predictors of pulmonary hypertension at 1 year follow-up after pulmonary embolism treated by catheter-directed therapies

Key Result

Baseline sPAP >60 mmHg (aOR 12.20) and prior deep-vein thrombosis (aOR 12.66) independently predict 1-year residual pulmonary hypertension after catheter therapy for pulmonary embolism.

Key Points

The goal is to identify 1-year predictors of pulmonary hypertension in patients treated with transcatheter interventions.
Analyzed data from 135 patients with pulmonary embolism treated via percutaneous methods.
Measured systolic pulmonary artery pressure at follow-up to define residual pulmonary hypertension.
Used logistic regression to determine independent predictors of pulmonary hypertension.
Residual pulmonary hypertension occurred in 11.1% of the patients at 1-year follow-up.
Higher baseline pulmonary artery pressure and prior deep-vein thrombosis were significant predictors.
Bilateral principal involvement in thrombus location was linked to lower odds of residual hypertension.

Structured PICO

Population

135 patients with pulmonary embolism treated with percutaneous therapy (from the USAT IH-PE Registry) who had echocardiographic follow-up available at 1 year

Intervention

Percutaneous therapy (catheter-directed transcatheter intervention)

Outcome

Residual pulmonary hypertension, defined as systolic pulmonary artery pressure (sPAP) >40 mmHg at ≈1 yearsurrogate

Severe baseline pulmonary hypertension and prior deep-vein thrombosis are strong independent predictors of residual pulmonary hypertension at 1 year in patients treated with percutaneous therapy for pulmonary embolism.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract Introduction Residual pulmonary hypertension (PH) after pulmonary embolism (PE) impairs functional recovery and survival. Among patients treated with percutaneous therapy, determinants of late PH are insufficiently characterized. We aimed to identify 1-year predictors of PH in a cohort treated with transcatheter intervention. Methods and Results Out of the 275 PE patients undergoing percutaneous treatment enrolled in the USAT IH-PE Registry, echocardiographic follow-up was available in 135. The primary endpoint was residual PH, defined as systolic pulmonary artery pressure (sPAP) 40 mmHg at ≈1 year, which occurred in 15/135 (11.1%). On univariable analyses, baseline sPAP 60 mmHg (30.8% vs 8.2%; p=0.014), prior deep-vein thrombosis (25.0% vs 8.2%; p=0.018), prior PE (30.0% vs 9.6%; p=0.048), and need for non-invasive ventilation (26.7% vs 9.5%; p=0.049) were associated with the endpoint; thrombus location across bilateral principal, bilateral lobar, and unilateral principal was related (p=0.017). Multivariable logistic regression identified baseline sPAP 60 mmHg (adjusted odds ratio aOR 12.20, 95% CI 1.73–85.98; p=0.012) and prior deep-vein thrombosis (aOR 12.66, 95% CI 1.53–104.61; p=0.018) as independent predictors. Bilateral principal involvement was associated with lower odds (aOR 0.092; p=0.029). Conclusions In PE patients after percutaneous therapy, severe baseline PH and prior venous thromboembolism identify high risk of 1-year residual PH.PASP across time points in both groupsFor image description, please refer to the figure legend and surrounding text.

Bookmark